

**DC BEAD™**  
Drug-eluting Bead

**DC BEAD LUMI™**  
Radiopaque Drug-eluting Bead

**UNIQUE SCIENCE  
UNIQUE EVIDENCE  
UNIQUE PERFORMANCE**



**ALL BEADS ARE NOT THE SAME**

## CONFIDENCE IN A GOLD-STANDARD\* HERITAGE...

All DC Bead products use the same unique chemistry and the same sulfonate ionic-exchange mechanism to achieve controlled and prolonged drug release profiles.

This unique chemistry is proven to deliver:

- Improved tolerability over cTACE with associated quality-of-life and cost benefits.<sup>1-9</sup>
- Sustained and controlled release of doxorubicin *in vivo* at therapeutically meaningful levels for more than one month.<sup>10</sup>

## DC BEAD FAMILY BIBLIOGRAPHY<sup>1</sup>

<b>DEBDOX</b>	 <b>131</b> publications	 <b>6856</b> patients
<b>DEBIRI</b>	 <b>31</b> publications	 <b>683</b> patients

No other drug-eluting bead is supported by the same level of research and clinical evidence as the DC Bead family

**Core Chemistry**  
Polyvinyl Alcohol

**Drug Binding Group**  
Sulfonate: AMPS




## ...WITH A UNIQUE CHEMISTRY...

Theoretical elution chart for illustrative purposes to demonstrate how variations in drug elution behaviour could influence the balance between efficacy and toxicity

If doxorubicin elution is too rapid, the drug is likely to reach the systemic circulation, causing toxicity. Efficacy may be reduced as the release cannot be sustained.

The ideal drug-eluting bead delivers a sustained dose of doxorubicin within the relevant therapeutic window.

If doxorubicin elution is too slow or incomplete, therapeutic levels in the tumour may not be sustained for long enough to achieve efficacy.



### How Does a Bead's Chemistry Impact Drug Delivery?

**Type of bond:** DC Bead uses a **sulfonate (AMPS)** bond. Studies have shown that beads that use a **carboxylate bond** may not deliver doxorubicin as effectively as DC Bead, with drug remaining "trapped" in the bead.<sup>11-13</sup>

**Frequency of bond:** The number of binding points is important. If there are too few:

- The prescribed dose might not completely load.
- The release may be uncontrolled and elute too quickly, risking toxicity and compromising sustained elution.

No other drug-eluting bead has the same core chemistry and the same elution profile as the DC Bead family<sup>12</sup>




## ...DEVELOPED WITHOUT COMPROMISE SO YOU CAN SEE MORE.


DC Bead LUMI were developed to offer increased information and control in the treatment of liver cancer with inherent, lasting radiopacity that enables:

- Real-time adjustments during LUMI-TACE to guide precise delivery of beads into the tumour.<sup>14-16</sup>
- Enhanced determination of embolisation endpoint.<sup>14-16</sup>
- Ability to discover and address regions of under treatment.<sup>14</sup>
- Precise evaluation and confident reporting of the completeness of tumour treatment.<sup>14,16</sup>
- Informed planning and treatment optimisation – including combining with ablation before or after LUMI-TACE.<sup>15,16</sup>

### Case study: Identification and resolution of undertreated tumour



Immediately after LUMI-TACE administered via what appeared to be only tumour-feeding vessel, non-contrast CBCT shows significant portion of tumour with no coverage



A second feeder branch is identified, via which a second LUMI-TACE administration is performed to achieve comprehensive coverage of the tumour

Images courtesy of Irene Bargellini, MD  
Pisa University Hospital, Pisa, Italy

**No other commercially available drug-eluting bead  
offers inherent and lasting radiopacity**



**UNIQUE SCIENCE  
UNIQUE EVIDENCE  
UNIQUE PERFORMANCE**

**Your choice of DC Bead is an evidence-based decision**

- ✓ Unique, clinically proven sulfonate (AMPS) drug-binding and release<sup>12,16-18</sup>
- ✓ Published doxorubicin and irinotecan elution curves<sup>17,19</sup>
- ✓ Histological confirmation of sustained and controlled release of doxorubicin *in vivo*<sup>10</sup>
- ✓ Pharmacokinetic data demonstrate low systemic exposure in clinical use<sup>18,20,21</sup>
- ✓ CE Mark approved indication statement includes loading with doxorubicin and irinotecan\*

**If your choice of bead is different,  
what evidence do you have?**

**ALL BEADS ARE NOT THE SAME**



## Ordering Information

	DC BEAD				DC BEAD LUMI
Size	70-150µm	100-300µm	300-500µm	500-700µm	70-150µm
Label Colour	Black and yellow	Yellow	Blue	Red	Black
Volume of Beads	2ml	2ml	2ml	2ml	2ml
Product Code	DC2V001	DC2V103	DC2V305	DC2V507	R02D001

## References

1. DC Bead Family Bibliography June 2019. All potential patient duplications removed.
2. Clouet J *et al.* *Diagn Interv Imaging*. 2014; 95(4): 427-34.
3. Megias Vericat JE *et al.* *Radiologia*. 2015; 57(6): 496-504.
4. Vadot L *et al.* *J Clin Pharm Ther*. 2015; 40(1): 83-90.
5. Cucchetti A *et al.* *Dig Liver Dis*. 2016 Jul; 48(7): 798-805.
6. Lammer J *et al.* *Cardiovasc Intervent Radiol*. 2010; 33(1): 41-52.
7. Arabi M *et al.* *Saudi J Gastroenterol*. 2015; 21(3): 175-80.
8. Recchia F *et al.* *Oncol Rep*. 2012; 27(5): 1377-83.
9. Kloeckner R *et al.* *BMC Cancer*. 2015; 15: 465.
10. Namur J *et al.* *J Hepatol*. 2011; 55: 1332-8.
11. Jordan O *et al.* *J Vasc Interv Radiol*. 2010; 21: 1084-90.
12. de Baere T *et al.* *J Vasc Interv Radiol*. 2016; 27: 1425-31.
13. Swaine TS *et al.* Poster presentation APS meeting, Nottingham, UK. September 2015.
14. Aliberti C *et al.* *Future Oncol* 2017; 13(25): 2243-52.
15. Reicher J *et al.* *Cardiovasc Intervent Radiol* 2019; 42(11): 1563-70.
16. Iezzi R *et al.* *Hepat Oncol* 2017; 4(3): 69-73.
17. Lewis AJ, Gonzalez V, Lloyd AW. *J Vasc Interv Radiol* 17 (2006): 335-42.
18. Varela M, Real MI, Burrell M *et al.* *J Hepatol* 46 (2007): 474-81.
19. Taylor R, Tang Y, Gonzalez MV *et al.* *Eur J Pharm Sci* 30 (2007): 7-14.
20. Lewis AL, Holden RR, Chung ST *et al.* *J Mater Sci Mater Med* 24 (2013): 115-27.
21. Rao PR, Pascale P, Seck A *et al.* *Cardiovasc Intervent Radiol* 35 (2012): 1448-59.

† This paper includes reference to loading DC Bead with idarubicin, which constitutes off-label use of DC Bead and is not endorsed by Boston Scientific. DC Bead is indicated for loading with doxorubicin and irinotecan only. Boston Scientific does not promote or endorse off-label use of its products.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

**Boston Scientific**  
Advancing science for life™

2020 Copyright  
© Boston Scientific Corporation  
or its affiliates. All rights reserved.  
PI-801705-AA